文献速递糖尿病

用AIRmax和静脉葡萄糖评估1型糖尿病高危人群的β细胞量与功能

Assessment of β Cell Mass and Function by AIRmax and Intravenous Glucose in High-Risk Subjects for Type 1 Diabetes.
PubMed 文献 · J Clin Endocrinol Metab · 2017-01-01

研究纳入40名1型糖尿病患者的亲属,分为低风险组(0-1种抗体,n=21)和高风险组(≥2种抗体,n=19),评估AIRmax与静脉葡萄糖耐量试验(IVGTT)的β细胞功能。AIRmax可重复且与IVGTT第一时相胰岛素反应(FPIR)相关(r=0.779);高风险组FPIR均值更低且低于异常阈值者更多(19例中10例(52.6%) vs 21例中4例(19%));低FPIR者AIRmax反应异质(38-250 μU/mL)。

要点

  • AIRmax可重复、耐受良好,与IVGTT的FPIR相关(r=0.779)。
  • 高风险组FPIR均值更低,低于异常阈值者比例更高(52.6% vs 19%)。
  • 低FPIR者AIRmax反应异质,提示β细胞量与功能关系存在差异。

核心结论

  • 以FPIR评估β细胞功能低下的家族成员中,AIRmax评估的胰岛素分泌储备存在显著变异。
  • AIRmax是β细胞量的功能指标,数据提示疾病发病机制异质,部分个体β细胞量相对功能得以保留。
  • AIRmax的耐受性和可重复性提示其可作为疾病修饰治疗临床试验的分层指标。

研究设计与样本

  • 研究纳入40名受试者:低风险组为0-1种抗体的1型糖尿病患者亲属(n=21),高风险组为≥2种抗体的亲属(n=19)。
  • 受试者在不同天进行两次IVGTT和AIRmax操作。

主要发现

  • AIRmax可重复、耐受良好,与IVGTT第一时相胰岛素反应(FPIR)相关(r=0.779)。
  • 高风险组较低风险组β细胞功能受损更重:FPIR均值更低,且低于既定异常功能阈值者更多(19例中10例(52.6%) vs 21例中4例(19%))。
  • 低FPIR受试者中AIRmax反应异质,范围为38至250 μU/mL。

关键数值与推荐

  • AIRmax与FPIR的相关系数r=0.779。
  • 高风险组FPIR低于异常阈值者10/19(52.6%),低风险组4/21(19%)。
  • 低FPIR者AIRmax范围为38至250 μU/mL。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: There is little information regarding β cell mass in individuals at early stages of type 1 diabetes (T1D). OBJECTIVE: To investigate both acute insulin response to arginine at hyperglycemia (AIRmax), as a correlate of β cell mass, and β cell function by the intravenous glucose tolerance test (IVGTT) in subjects at early stages of T1D. DESIGN/SETTING/PARTICIPANTS: Forty subjects were enrolled: (1) low-risk group: relatives of patients with T1D with 0 to 1 antibody (n = 21) and (2) high-risk group: relatives with ≥2 antibodies (n = 19). MAIN OUTCOME MEASURE: Acute insulin and C-peptide responses to IVGTT and to AIRmax. Participants underwent two IVGTT and AIRmax procedures on different days. RESULTS: AIRmax was reproducible, well tolerated, and correlated to first-phase insulin response (FPIR) from IVGTT (r = 0.779). The high-risk group had greater impaired β cell function compared with the low-risk group, determined both by lower mean FPIR and a greater number of subjects below an established threshold for abnormal function [10 of 19 (52.6%) versus 4 of 21 (19%)]. There was a heterogeneous AIRmax response in these subjects with low FPIR, ranging from 38 to 250 μU/mL. CONCLUSIONS: There is significant variation in insulin secretory reserve as assessed by AIRmax in family members with low β cell function assessed by FPIR. As AIRmax is a functional measure of β cell mass, these data suggest heterogeneity in disease pathogenesis in which mass is preserved in relation to function in some individuals. The tolerability and reproducibility of AIRmax suggest it could be a useful stratification measure in clinical trials of disease-modifying therapy.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Hao W, Woodwyk A, Beam C, et al. Assessment of β Cell Mass and Function by AIRmax and Intravenous Glucose in High-Risk Subjects for Type 1 Diabetes. J Clin Endocrinol Metab. 2017. PMID: 29040630. doi:10.1210/jc.2017-01713

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。